Hot Features
プレミアム
Akcea Therapeutics Inc (AKCA)
NASDAQ
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif., Oct...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif., Oct. 12...
National Institute for Health and Care Excellence (NICE) issues a positive recommendation for volanesorsen to treat adults with Familial Chylomicronaemia Syndrome (FCS) Akcea Therapeutics UK...
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics - Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash - Transaction...
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant...
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020 Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent...
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020 Late-breaking presentation to focus on efficacy and safety data of vupanorsen in...
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020 Data presentation will highlight efficacy, safety and tolerability of...
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in...
Akcea Reports Financial Results and Highlights for Second Quarter 2020 Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year Achieved Pricing and Reimbursement Across Key...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Sidney
7年前
Thoro
7年前
Rodney213
7年前
dinosaurbob
7年前
Thoro
7年前
dinosaurbob
7年前
dinosaurbob
7年前
dinosaurbob
7年前
dinosaurbob
7年前
dinosaurbob
7年前
Thoro
7年前
dinosaurbob
7年前
Thoro
7年前
dinosaurbob
7年前
Thoro
7年前
dinosaurbob
7年前
Thoro
7年前
Thoro
7年前
Thoro
7年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
